Proactive Investors - Run By Investors For Investors

CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

This is a niche space that is growing fast and CannPal already has an advantage through its research and product development programs which are well underway.
a dog and a man
CannPal recently received key ethics approvals to progress its lead therapeutic products

CannPal Animal Therapeutics Ltd (ASX:CP1) is well placed to benefit from the rapidly growing cannabinoids-based animal health market.

Focusing on animal well-being, particularly companion pets (e.g., cats and dogs) could be lucrative for the company.

According to the American Pet Product Association, annual pet industry expenditure in the U.S. has grown in each of the past 18 years, with Americans estimated to have spent $18.3 billion on veterinary care and $15.5 billion on supplies and over-the-counter medicines in 2018.

READ: CannPal Animal Therapeutics receives approvals for two clinical studies

The company recently received two key ethics approvals to progress the research and development of its lead therapeutic products, CPAT-01 and DermaCann.

CPAT-01 is a pain and inflammatory control being developed for dogs and DermaCann is a nutraceutical product in development to promote canine skin health.

CannPal hopes to complete recruitment for both studies by mid CY2019.

Elixinol Global gaining traction in the pet space

Many players in the industrial hemp and cannabidiol (CBD) based dietary supplement market are seeing a growing market for their products catering to the pet industry.

This includes Elixinol Global Ltd (ASX:EXL), manufacturer of Edibites, a CBD pet treat specifically formulated for dogs.

Elixinol recently witnessed an increase in private label production which now accounts for around 40% of its U.S. revenue of $32.5 million in 2018, with one large customer in the pet space driving most of the private label growth.

Cannabinoids-based animal health is a niche space that is growing fast and CannPal already has an advantage through its research and product development programs which are well underway.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CP1 profile View Profile

CannPal Animal Therapeutics Ltd Timeline

Related Articles

cannabis leaf
May 09 2019
The company plans to leverage its portfolio of brands as well as its distribution network of more than 39,000 European pharmacies to maximize margins and profitability
Sydney Harbour Bridge
January 23 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
cannabis plant
December 15 2018
The Vancouver-based cannabis group services medical and recreational cannabis markets in Canada and internationally

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use